At Roswell Park's Center for Immunotherapy (CFI), our team of researchers is leading the effort to harness the immune system in the fight against cancer. This multidisciplinary team science approach is singularly focused on developing effective immunotherapies for cancer patients.
To achieve this goal, we have placed a strong emphasis on conducting innovative, high-impact phase I/II clinical trials of novel immunotherapeutic regimens developed by our research faculty. These approaches include testing cellular therapy, cancer vaccines, oncolytic viral therapy, and immune-response modifiers such as checkpoint blockade.
This intellectual capital, brought together with three core facilities to conduct the clinical trials in partnership with industry and academic centers, has put Roswell Park on the fast track toward developing effective and new immunotherapies.
We are proud to have assembled these complementary components of immunotherapy research under one umbrella in synergy and believe this will help cancer patients reinforce their bodies' immunological defenses to treat, control and prevent cancer.
Kunle Odunsi, MD, PhD, FRCOG, FACOG
Executive Director, Center for Immunotherapy
Chair, Department of Gynecologic Oncology
The M. Steven Piver Professor of Gynecologic Oncology
Co-Leader, Tumor Immunology and Immunotherapy Program